AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. The company is headquartered in Mason, Ohio.
| Revenue (TTM) | $534.53M |
| Gross Profit (TTM) | $400.78M |
| EBITDA | $11.08M |
| Operating Margin | 1.77% |
| Return on Equity | -2.40% |
| Return on Assets | -0.94% |
| Revenue/Share (TTM) | $11.19 |
| Book Value | $9.88 |
| Price-to-Book | 2.98 |
| Price-to-Sales (TTM) | 2.73 |
| EV/Revenue | 2.571 |
| EV/EBITDA | 84.60 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 13.10% |
| Shares Outstanding | $50.63M |
| Float | $47.79M |
| % Insiders | 3.77% |
| % Institutions | 95.09% |
Volatility is currently expanding